What is Pfizer's tukysa — intangible asset impairments?

Pfizer (PFE) reported tukysa — intangible asset impairments of $205.00M in Q4 2025.

How has Pfizer's tukysa — intangible asset impairments changed year-over-year?

Pfizer's tukysa — intangible asset impairments decreased by 48.8% year-over-year, from $400.00M to $205.00M.

Products & Services · Intangible asset impairments

Tukysa — Intangible asset impairments

Pfizer Tukysa — Intangible asset impairments remained flat by 0.0% to $205.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 48.8%, from $400.00M to $205.00M.

Analysis

StatementSegment

First reportedQ4 2024

Last reportedQ4 2025Feb 26, 2026

Rolls up toImpairment Charges

Metric ID: pfe_segment_tukysa_intangible_asset_impairments

Historical Data

5 periods

	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25
Value	$400.00M	$205.00M	$205.00M	$205.00M	$205.00M
QoQ Change	—	-48.8%	+0.0%	+0.0%	+0.0%
YoY Change	—	—	—	—	-48.8%

Range$205.00M – $400.00M

CAGR-48.8%

Avg YoY Growth-48.8%

Median YoY Growth-48.8%

Current Streak3 quarters growth

Frequently Asked Questions

What is Pfizer's tukysa — intangible asset impairments?: Pfizer (PFE) reported tukysa — intangible asset impairments of $205.00M in Q4 2025.
How has Pfizer's tukysa — intangible asset impairments changed year-over-year?: Pfizer's tukysa — intangible asset impairments decreased by 48.8% year-over-year, from $400.00M to $205.00M.